The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
대표청구항▼
What is claimed is: 1. A composition of matter of the formula (X1)a—F1—(X2)b and multimers thereof, wherein: F1 is an IgG4 Fc domain comprising SEQ ID NO: 607 modified so that it comprises at least one X3 inserted into or replacing all or part of a sequence selected from SEQ ID N
What is claimed is: 1. A composition of matter of the formula (X1)a—F1—(X2)b and multimers thereof, wherein: F1 is an IgG4 Fc domain comprising SEQ ID NO: 607 modified so that it comprises at least one X3 inserted into or replacing all or part of a sequence selected from SEQ ID NOS: 620, 621, 624, 627, 632, 634, 638, 639, 643, and 644 within a loop region of the IgG4 Fc domain, said loop region being in a non-terminal domain of the Fc domain; X1 and X2 are each independently selected from —(L1)c—P1, —(L1)c—P1—(L2)d—P2, —(L1)c—P1—(L2)d—P2—(L3)e—P3 and —(L1)c—P1—(L2)d—P2—(L3)e—P3—(L4)f—P4; X3 is independently selected from —(L5)c—P5, —(L5)c—P5—(L6)d—P6, —(L5)c—P5—(L6)d—P6—(L7)e—P7, and —(L5)c—P5—(L6)d—P6—(L7)e—P7—(L8)f—P8; P1, P2, P3, and P4 are each independently sequences of pharmacologically active polypeptides or pharmacologically active peptides; P5, P6, P7, and P8 are each independently sequences of pharmacologically active peptides; L1, L2, L3, L4, L5, L6, L7, and L8 are each independently linkers; and a, b, c, d, e, and f are each independently 0 or 1. 2. The composition of matter of claim 1, wherein X3 is inserted at Q50/E51, F78/N79, N107/K108, M140/T141, Q168/P169, E170/N171, S182/D183, G184/S185, or G202/N203. 3. The composition of matter of claim 1, wherein X3 comprises a myostatin binding peptide sequence, an erythropoietin-mimetic (EPO-mimetic) peptide sequence, an angiotensin-2 (ang-2) binding peptide sequence, a thrombopoietin-mimetic (TPO-mimetic) peptide sequence, an angiotensin-2 (ang-2) binding peptide sequence, a nerve growth factor (NGF) binding peptide sequence, or a B cell activating factor (BAFF) binding peptide sequence. 4. The composition of matter of claim 3, wherein the myostatin binding peptide sequence is selected from SEQ ID NOS: 218 to 509. 5. The composition of matter of claim 3, wherein the EPO-mimetic peptide sequence is selected from SEQ ID NOS: 1 to 27. 6. The composition of matter of claim 3, wherein the TPO-mimetic peptide sequence is selected from SEQ ID NOS: 28 to 99. 7. The composition of matter of claim 3, wherein the ang-2 binding peptide sequence is selected from SEQ ID NOS: 100 to 189. 8. The composition of matter of claim 3, wherein the NGF binding peptide sequence is selected from SEQ ID NOS: 190 to 218. 9. The composition of matter of claim 3, wherein the BAFF binding peptide sequence is selected from SEQ ID NOS: 510 to 594. 10. A modified antibody, comprising an Fc domain, F1, wherein: F1 is an IgG4 Fc domain comprising SEQ ID NO: 607 modified so that it comprises at least one X3 inserted into or replacing all or part of a sequence selected from SEQ ID NOS: 620, 621, 624, 627, 632, 634, 638, 639, 643, and 644 within a loop region of the IgG4 Fc domain, said loop region being in a non-terminal domain of the Fc domain, wherein: X3 is independently selected from —(L5)c—P5, —(L5)c—P5—(L6)d—P6, —(L5)c—P5—(L6)d—P6—(L7)e—P7, and —(L5)c—P5—(L6)d—P6—(L7)e—P7—(L8)f—P8; P5, P6, P7, and P8 are each independently sequences of pharmacologically active peptides; L5, L6, L7, and L8 are each independently linkers; and c, d, e, and f are each independently 0 or 1. 11. The modified antibody of claim 10, wherein X3 is inserted at Q50/E51, F78/N79, N107/K108 M140/T141, Q168/P169, E170/N171, S182/D183, G184/S185, or G202/N203. 12. The modified antibody of claim 10, wherein X3 comprises a myostatin binding peptide sequence, an erythropoietin-mimetic (EPO-mimetic) peptide sequence, a thrombopoietin-mimetic (TPO-mimetic) peptide sequence, an angiotensin-2 (ang-2) binding peptide sequence, a nerve growth factor (NGF) binding peptide sequence, or a B cell activating factor (BAFF) binding peptide sequence. 13. The modified antibody of claim 12, wherein the myostatin binding peptide sequence is selected from SEQ ID NOS: 218 to 509. 14. The modified antibody of claim 12, wherein the EPO-mimetic peptide sequence is selected from SEQ ID NOS: 1 to 27. 15. The modified antibody of claim 12, wherein the TPO-mimetic peptide sequence is selected from SEQ ID NOS: 28 to 99. 16. The modified antibody of claim 12, wherein the ang-2 binding peptide sequence is selected from SEQ ID NOS: 100 to 189. 17. The modified antibody of claim 12, wherein the NGF binding peptide sequence is selected from SEQ ID NOS: 190 to 218. 18. The modified antibody of claim 12, wherein the BAFF binding peptide sequence is selected from SEQ ID NOS: 510 to 594.
Ayers John S. (Palmerston North NZX) Bethell Geoffrey S. (Palmerston North NZX) Hancock William S. (Palmerston North NZX) Hearn Milton T. W. (Dunedin North NZX), Activated matrix and method of activation.
Goodwin Raymond G. (Seattle WA) Smith Craig A. (Seattle WA) Armitage Richard J. (Bainbridge Island WA) Gruss Hans-Juergen (Bainbridge Island WA), CD30 ligand.
Jaworek Dieter (Weilheim ; Upper Bavaria DT) Nelbock-Hochstetter Michael (Tutzing DT) Beaucamp Klaus (Tutzing DT) Bergmeyer Hans Ulrich (Tutzing DT) Botsch Karl-Heinz (Bernried DT), Carrier-bound protein prepared by reacting the protein with an acylating or alkylating compound having a carrier-bonding.
Schneider Michael (Ottobrunn-Riemerling DEX) Wernicke Hans J. (Geretsried DEX) Kochloefl Karl (Bruckmhl/Heufeld DEX) Maletz Gerd (Landshut DEX), Catalyst for decreasing the content of nitrogen oxides in flue gases.
Wrighton Nicholas C. ; Dower William J. ; Chang Ray S. ; Kashyap Arun K. ; Jolliffe Linda K. ; Johnson Dana ; Mulcahy Linda, Compounds and peptides that bind to the erythropoietin receptor.
Lasky Laurence A. (Sausalito CA) Rosen Steven D. (San Francisco CA) Stachel Scott E. (Berkeley CA) Singer Mark S. (Berkeley CA) Yednock Ted A. (Fairfax CA), DNA sequence encoding a functional domain of a lymphocyte homing receptor.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
McKenzie Ian F. C.,AUX ; Hogarth Mark P.,AUX ; Hibbs Margaret L.,AUX ; Scott Bernadette M.,AUX ; Bonadonna Lisa,AUX ; Hulett Mark D.,AUX, FC receptor for immunoglobulin.
Woodle Martin C. (Menlo Park CA) Martin Francis J. (San Francisco CA) Yau-Young Annie (Los Altos CA) Redemann Carl T. (Walnut Creek CA), Liposomes with enhanced circulation time.
Lasky Laurence A. (Sausalito CA) Rosen Steven D. (San Francisco CA) Stachel Scott E. (Berkeley CA) Singer Mark S. (Berkeley CA) Yednock Ted A. (Fairfax CA), Lymphocyte homing receptors.
Sledziewski Andrzej Z. ; Bell Lillian Anne ; Kindsvogel Wayne R., Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions.
Davis Frank F. (19 Farmingdale Rd. East Brunswick NJ 08816) Van Es Theodorus (313 Overbrook Rd. Piscataway NJ 08854) Palczuk Nicholas C. (45 W. Franklin St. Bound Brook NJ 08805), Non-immunogenic polypeptides.
Schatz Peter J. (Mountain View CA) Cull Millard G. (Oakland CA) Miller Jeff F. (Los Angeles CA) Stemmer Willem P. C. (Los Gatos CA), Peptide library and screening method.
Dower William J. ; Barrett Ronald W. ; Cwirla Steven E. ; Gates Christian M. ; Schatz Peter J. ; Balasubramanian Palaniappan ; Wagstrom Christopher R. ; Hendren Richard Wayne ; DePrince Randoph B. ; , Peptides and compounds that bind to a receptor.
Barrett Ronald W. ; Yanofsky Stephen D. ; Baldwin David ; Jacobs Jeff W. ; Bovy Phillipe R. ; Leahy Ellen M. ; Pottorf Richard S., Peptides and compounds that bind to the IL-1 receptor.
Yanofsky Stephen D. (San Mateo CA) Barrett Ronald W. (Sunnyvale CA) Baldwin David N. (Palo Alto CA) Jacobs Jeff W. (San Mateo CA), Peptides and compounds that bind to the IL-1 receptor.
Barrett Ronald W. ; Dower William J. ; Cwirla Steven E. ; Johnson Sherril S. ; Wrighton Nicholas C. ; Duffin David J. ; Wagstrom Christopher R., Peptides and compounds that bind to the thrombopoietin receptor.
Duchesne Marc,FRX ; Faucher Didier,FRX ; Parker Fabienne,FRX ; Schweighoffer Fabien,FRX ; Tocque Bruno,FRX, Peptides capable of binding to the GAP protein SH3 domain, nucleotide sequences coding therefor, and preparation and us.
Hanafusa Hidesaburo ; Knudsen Beatrice S. ; Feller Stephan M. ; Kuriyan John ; Wu Xiaodong ; Zheng Jie ; Cowburn David, Peptides specific for the first Crk-SH3 domain.
Hodgins Leonard T. (New York NY) Finlay Thomas H. (Ridgewood NJ) Johnson Alan J. (New York NY), Preparation of trichloro-s-triazine activated supports for coupling ligands.
Platz Robert M. (Half Moon Bay CA) Winters Mark A. (Mountain View CA) Pitt Colin G. (Thousand Oaks CA), Pulmonary administration of granulocyte colony stimulating factor.
Takenaka Koichi,JPX ; Kobayashi Makoto,JPX ; Nishikawa Tomoharu,JPX ; Yasunaga Hideaki,JPX, developing method using an oscillated electric field and including a specified toner and carrier.
Gurney, Austin L.; Lewicki, John; Satyal, Sanjeev; Hoey, Timothy, Human frizzled (FZD) receptor polypeptides and methods of use thereof for treating cancer and inhibiting growth of tumor cells.
Gurney, Austin; Lewicki, John; Satyal, Sanjeev H.; Hoey, Timothy, Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor.
Gurney, Austin L.; Sato, Aaron Ken; Axelrod, Fumiko Takada; Hoey, Timothy Charles; Satyal, Sanjeev H.; Mitra, Satyajit Sujit Kumar, Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8.
Gurney, Austin; Lewicki, John; Satyal, Sanjeev; Hoey, Timothy, Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cell.
Ruker, Florian; Himmler, Gottfried; Wozniak-Knopp, Gordana, Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions.
Sun, Jeonghoon; Tam, Lei-Ting Tony; Han, Huiquan; Kwak, Keith Soo-Nyung; Zhou, Xiaolan, Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.